PL2420491T3 - 3,5-Podstawione piperydyny jako inhibitory reniny - Google Patents

3,5-Podstawione piperydyny jako inhibitory reniny

Info

Publication number
PL2420491T3
PL2420491T3 PL11185536T PL11185536T PL2420491T3 PL 2420491 T3 PL2420491 T3 PL 2420491T3 PL 11185536 T PL11185536 T PL 11185536T PL 11185536 T PL11185536 T PL 11185536T PL 2420491 T3 PL2420491 T3 PL 2420491T3
Authority
PL
Poland
Prior art keywords
piperidine compounds
renin inhibitors
substitued
substitued piperidine
renin
Prior art date
Application number
PL11185536T
Other languages
English (en)
Inventor
Takeru Ehara
Fumiaki Yokokawa
Philipp Grosche
Osamu Irie
Yuki Iwaki
Takanori Kanazawa
Shimpei Kawakami
Kazuhide Konishi
Muneto Mogi
Masaki Suzuki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37875514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2420491(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0604223A external-priority patent/GB0604223D0/en
Priority claimed from GB0611390A external-priority patent/GB0611390D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2420491T3 publication Critical patent/PL2420491T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11185536T 2005-12-30 2006-12-28 3,5-Podstawione piperydyny jako inhibitory reniny PL2420491T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05028771 2005-12-30
GB0604223A GB0604223D0 (en) 2006-03-02 2006-03-02 Organic compounds
GB0611390A GB0611390D0 (en) 2006-06-08 2006-06-08 Organic compounds
EP11185536.7A EP2420491B1 (en) 2005-12-30 2006-12-28 3 , 5-substitued piperidine compounds as renin inhibitors
EP06829892.6A EP1968940B1 (en) 2005-12-30 2006-12-28 3 , 5-substitued piperidine compounds as renin inhibitors

Publications (1)

Publication Number Publication Date
PL2420491T3 true PL2420491T3 (pl) 2013-12-31

Family

ID=37875514

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11185536T PL2420491T3 (pl) 2005-12-30 2006-12-28 3,5-Podstawione piperydyny jako inhibitory reniny

Country Status (20)

Country Link
US (1) US8129411B2 (pl)
EP (2) EP2420491B1 (pl)
JP (1) JP5306821B2 (pl)
KR (1) KR20080086921A (pl)
AR (1) AR058885A1 (pl)
AU (1) AU2006332124B2 (pl)
BR (1) BRPI0620736A2 (pl)
CA (1) CA2633624C (pl)
CR (1) CR10091A (pl)
EC (1) ECSP088587A (pl)
ES (2) ES2476422T3 (pl)
IL (1) IL192024A0 (pl)
MA (1) MA30073B1 (pl)
NO (1) NO20083315L (pl)
NZ (1) NZ569135A (pl)
PE (2) PE20110117A1 (pl)
PL (1) PL2420491T3 (pl)
PT (1) PT2420491E (pl)
TW (1) TW200738698A (pl)
WO (1) WO2007077005A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
NZ569135A (en) 2005-12-30 2011-08-26 Novartis Ag 3,5-Substituted piperidine compounds as renin inhibitors
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2009000811A1 (en) * 2007-06-25 2008-12-31 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
AU2008339351B2 (en) 2007-12-19 2013-02-28 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic derivative
NZ589019A (en) 2008-05-05 2012-10-26 Merck Frosst Canada Ltd 3, 4 - substituted piperidine derivatives as renin inhibitors
JO3465B1 (ar) 2008-06-19 2020-07-05 Takeda Pharmaceuticals Co مركب متغاير الحلقه واستخدامه
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP2421828A2 (en) * 2009-04-24 2012-02-29 Cadila Healthcare Limited Piperidine derivatives as inhibitors of renin
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
JP5331883B2 (ja) 2009-06-24 2013-10-30 大日本住友製薬株式会社 Ｎ−置換−環状アミノ誘導体
KR20140092696A (ko) * 2013-01-16 2014-07-24 주식회사유한양행 신규의 페닐에티닐 벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
WO2015156346A1 (ja) * 2014-04-10 2015-10-15 武田薬品工業株式会社 複素環化合物の製造法
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
US9643927B1 (en) * 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2018183911A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN117986146A (zh) * 2023-12-22 2024-05-07 河南优凯制药有限公司 一种枸橼酸喷托维林杂质的制备方法及其检测方法
CN119059970B (zh) * 2024-08-30 2026-03-24 上海信诺维生物医药有限公司 一种btk抑制剂药物中间体的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224941B (pl) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
NZ246441A (en) 1991-12-18 1996-02-27 Schering Corp Imidazol or imidazolalkyl substituted with a 4 or 5 membered nitrogen containing heterocycle, preparation and pharmaceutical compositions thereof
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
PL193686B1 (pl) 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
JP2000500502A (ja) * 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
CA2298813A1 (en) 1997-08-28 1999-03-04 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
WO1999065867A1 (en) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
JP2002528543A (ja) 1998-10-30 2002-09-03 メルク エンド カムパニー インコーポレーテッド トロンビン阻害剤
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
AU3386500A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
AU3389300A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU3818900A (en) 1999-04-14 2000-11-02 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
CN1481377A (zh) 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
KR100769381B1 (ko) * 2000-04-04 2007-10-22 브랜데이스 유니버시티 메소 화합물을 촉매 비대칭 탈대칭화시키는 방법
FR2811673B1 (fr) 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
EP1326619A2 (en) 2000-10-11 2003-07-16 Merck & Co., Inc. Pyrrolidine modulators of ccr5 chemokine receptor activity
US20060079533A1 (en) 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
EP1427408A4 (en) 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
CA2483241C (en) 2002-04-29 2011-05-31 Actelion Pharmaceuticals Ltd Novel diazabicyclononene derivatives
US6878722B2 (en) 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
US20060217371A1 (en) 2003-04-28 2006-09-28 Olivier Bezencon Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
CN1972912A (zh) 2003-04-29 2007-05-30 埃科特莱茵药品有限公司 新型3,4－二取代的1,2,3,6－四氢吡啶衍生物
CN1780663A (zh) 2003-04-30 2006-05-31 埃科特莱茵药品有限公司 作为肾素抑制剂的新型3－位具有杂原子的9－氮杂双环壬烯衍生物
US20060205768A1 (en) 2003-04-30 2006-09-14 Olivier Bezencon Tropane derivatives and their use as ace inhibitors
BRPI0409818A (pt) 2003-04-30 2006-05-09 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
MXPA05011711A (es) 2003-05-02 2006-01-23 Actelion Pharmaceuticals Ltd Derivados de diazabiciclononeno.
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
CN1863773A (zh) 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
BRPI0416976A (pt) 2003-11-26 2007-02-21 Novartis Ag derivados de 4-fenilpiperidina como inibidores de renina
EP1689702B1 (en) 2003-11-26 2013-01-30 Novartis AG Organic compounds
BRPI0506491A (pt) 2004-01-23 2007-02-13 Speedel Experimenta Ag compostos orgánicos
CA2553836A1 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their use as renin inhibitors
ATE472524T1 (de) 2004-01-23 2010-07-15 Novartis Ag Diaminoalkohole und deren verwendung als renininhibitoren
CN1934083A (zh) 2004-03-19 2007-03-21 斯皮德尔实验股份公司 作为肾素抑制剂用于治疗高血压的5－氨基－4－羟基－7－(1h－吲哚基甲基)－8－甲基壬酰胺衍生物
CA2560195A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
AR053406A1 (es) 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
AR053826A1 (es) 2005-03-11 2007-05-23 Speedel Experimenta Ag Compuestos organicos
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
JP2008535825A (ja) 2005-03-31 2008-09-04 シュペーデル・エクスペリメンタ・アーゲー レニン阻害剤としての３，４，５−置換ピペリジン
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
AR057816A1 (es) 2005-09-17 2007-12-19 Speedel Experimenta Ag Compuestos organicos
BRPI0617166A2 (pt) 2005-09-17 2011-07-12 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(imidazo[1,2-a]piridin-6-ilmetil)-8-me til-nonamidia e compostos relacionados como inibidores de renina para o tratamento de hipertensão
PE20071079A1 (es) 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
NZ569135A (en) 2005-12-30 2011-08-26 Novartis Ag 3,5-Substituted piperidine compounds as renin inhibitors
EP1816122A3 (en) 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
BRPI0706778A2 (pt) 2006-01-30 2011-04-05 Speedel Experimenta Ag processos para a preparação estéreo-seletiva de álcoois a partir de compostos alfa, beta-insaturados
AR061265A1 (es) 2006-06-08 2008-08-13 Speedel Experimenta Ag Piperidinas 2,5- disustituidas
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors

Also Published As

Publication number Publication date
JP2009522226A (ja) 2009-06-11
ES2430139T3 (es) 2013-11-19
TW200738698A (en) 2007-10-16
EP2420491B1 (en) 2013-07-03
ES2476422T3 (es) 2014-07-14
NZ569135A (en) 2011-08-26
EP1968940B1 (en) 2014-04-02
PE20071177A1 (es) 2008-01-18
JP5306821B2 (ja) 2013-10-02
AU2006332124B2 (en) 2011-03-03
WO2007077005A1 (en) 2007-07-12
PT2420491E (pt) 2013-10-14
EP1968940A1 (en) 2008-09-17
ECSP088587A (es) 2008-07-30
AR058885A1 (es) 2008-02-27
KR20080086921A (ko) 2008-09-26
EP2420491A1 (en) 2012-02-22
BRPI0620736A2 (pt) 2011-12-20
US20090192148A1 (en) 2009-07-30
CR10091A (es) 2008-10-27
PE20110117A1 (es) 2011-03-07
AU2006332124A1 (en) 2007-07-12
US8129411B2 (en) 2012-03-06
MA30073B1 (fr) 2008-12-01
CA2633624A1 (en) 2007-07-12
CA2633624C (en) 2013-11-19
IL192024A0 (en) 2008-12-29
NO20083315L (no) 2008-09-19

Similar Documents

Publication Publication Date Title
IL192024A0 (en) 3,5-substituted piperidine compounds as renin inhibitors
TWI369351B (en) 2,4-diamino-pyrimidines as aurora inhibitors
IL186130A0 (en) 3,4,5-substituted piperidines as renin inhibitors
PL1833816T3 (pl) Podstawione piperydyny jako inhibitory reniny
IL186124A0 (en) 3,4,5-substituted piperidines as renin inhibitors
IL180242A0 (en) Piperidine derivatives as renin inhibitors
IL186117A0 (en) Substituted piperidines as renin inhibitors
IL192053A0 (en) 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
ZA200804762B (en) 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
IL191711A0 (en) 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
ZA200804393B (en) Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors
EP1844003A4 (en) NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
ZA200810640B (en) 1,5 -Diphenylpyrazoles II as HSP90 Inhibitors
IL192227A0 (en) Amorphous form of 1,2-dihydropyridine compound
AP2007004171A0 (en) Novel compounds
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
EP1868612A4 (en) NOVEL CONNECTIONS
EP1868611A4 (en) NOVEL CONNECTIONS
ZA200804956B (en) 3,5-substituted piperidine compounds as renin inhibitors
IL187533A0 (en) Novel piperidine derivative
GB0500140D0 (en) Novel compounds
EP1869026A4 (en) NEW CONNECTIONS
HK1121445A (en) 3, 5-substitued piperidine compounds as renin inhibitors
HK1110311A (en) 3,4,5-substituted piperidines as renin inhibitors